We’re thrilled to announce that Via Harrow has successfully sustained its hepatitis C micro-elimination status for over one year. This marks an incredible milestone, as Harrow is the first Via service to achieve and sustain this status.
A massive shoutout to everyone involved, especially to our clinical team and BBV champion, for their critical roles in this achievement. Also a special thank you to our incredible recovery practitioners, who tirelessly carry out dry blood spot tests for those beginning their treatment journey with us, working to ensure no one is left behind.
Oasis Azeez-Harris, senior public health commissioner for sexual health and substance misuse from Harrow Council, said, ‘Congratulations to the Via Harrow team for their achievement of maintaining one full year of hep C micro-elimination. I am thrilled to celebrate their remarkable achievement of hepatitis C micro-elimination for the second consecutive year. Their dedication and hard work in combatting this virus is truly commendable. This milestone is a testament to their unwavering commitment to improving public health and making a significant difference in the community. Via Harrow’s efforts do not only bring hope to many but have also set a shining example for others to follow. Keep up the fantastic work and know that your contributions are deeply appreciated. Warmest congratulations once again.’
Dr Vivienne Gosnell, clinical lead at Via Harrow, said, ‘Congratulations to all at Via Harrow for sustaining hep-C micro-elimination for over one year. It’s been a joint effort, and we are very grateful for the support centrally from our hep C co-ordinator making sure we had reliable, up-to-date data. We met regularly and shared this with our team to ensure testing opportunities wouldn’t be missed. We also worked closely with our hospital infectious diseases unit and the Hepatitis C Trust mentors to reach those not attending the service. Successful hepatitis C treatment not only prevents long-term health complications such as cirrhosis and liver cancer for those affected, but also stops transmission to others. We want to thank everyone involved for their hard work and dedication in achieving this goal.’
This blog was originally published by Via. You can read the original post here.
DDN magazine is a free publication self-funded through advertising.
We are proud to work in partnership with many of the leading charities and treatment providers in the sector.
This content was created by Via